As CRC patients with CRC tumours of the UICC Stages II–III have a higher risk of distant recurrence [27], we specifically analysed this subgroup of tumour samples and indeed found a significant increase of S100P expression in tumours of patients with metachronous metastasis (P < 0.05; N = 43; Fig. 5b, left). The gene discussed is S100P; the disease is neoplasm.